IHS Chemical Week

EnviroTech :: Biotech

Sanofi-Aventis Signs Licensing Agreement with U.S. Biotech Firm

4:14 AM MDT | October 2, 2009 | Deepti Ramesh

Sanofi-Aventis (Paris) says it has entered into an exclusive global collaboration and licensing agreement with biotechnology company Merrimack Pharmaceuticals (Cambridge, MA) for MM-121, a monoclonal antibody in oncology. MM-121 is currently in Phase 1 clinical testing. Sanofi-Aventis will receive an exclusive worldwide license to develop, manufacture and commercialize MM-121, under the terms of the deal. Merrimack will retain potential co-promotion rights in the U.S. MM-121 is a pioneering monoclonal antibody which brings a new innovative approach to...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2012 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa